U.S. Intravenous Solutions Market (2025 - 2030) Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals), By End-use (Home, Hospitals), And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Product
                        1.2.2. Nutrients
                        1.2.3. End Use
                        1.2.4. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Volume price analysis (Model 2)
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Product outlook
                        2.2.2. Nutrients’ outlook
                        2.2.3. End use outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Intravenous Solutions Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Increasing prevalence of chronic diseases
                            3.2.1.2. Aging population
                            3.2.1.3. Advancements in medical technology
                        3.2.2. Market restraint analysis
                            3.2.2.1. High costs associated with IV therapy due to shortages
                            3.2.2.2. Risk of complications
                    3.3. U.S. Intravenous Solutions Market Analysis Tools
                        3.3.1. Industry Analysis – Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
                        3.3.3. Pipeline Analysis
Chapter 4. U.S. Intravenous Solutions Market: Product Estimates & Trend Analysis
                    4.1. Global U.S. Intravenous Solutions Market: Product Dashboard
                    4.2. Global U.S. Intravenous Solutions Market: Product Movement Analysis
                    4.3. Global U.S. Intravenous Solutions Market by Product, Revenue
                    4.4. Total Parenteral Nutrition (TPN)
                        4.4.1. Total parenteral nutrition (TPN) market estimates and forecasts 2018 to 2030 (USD Billion)
                    4.5. Peripheral Parenteral Nutrition (PPN)
                        4.5.1. Peripheral parenteral nutrition (PPN) market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 5. U.S. Intravenous Solutions Market: Nutrients Estimates & Trend Analysis
                    5.1. Global U.S. Intravenous Solutions Market: Nutrients Dashboard
                    5.2. Global U.S. Intravenous Solutions Market: Nutrients Movement Analysis
                    5.3. Global U.S. Intravenous Solutions Market by Nutrients, Revenue
                    5.4. Carbohydrates
                        5.4.1. Carbohydrates market estimates and forecasts 2018 to 2030 (USD Billion)
                    5.5. Single Dose Amino Acids
                        5.5.1. Single dose amino acids market estimates and forecasts 2018 to 2030 (USD Billion)
                    5.6. Vitamins And Minerals
                        5.6.1. Vitamins and minerals market estimates and forecasts 2018 to 2030 (USD Billion)
                    5.7. Parenteral Lipid Emulsion
                        5.7.1. Parenteral lipid emulsion market estimates and forecasts 2018 to 2030 (USD Billion)
                    5.8. Others
                        5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 6. U.S. Intravenous Solutions Market: End Use Estimates & Trend Analysis
                    6.1. Global U.S. Intravenous Solutions Market: End Use Dashboard
                    6.2. Global U.S. Intravenous Solutions Market: End Use Movement Analysis
                    6.3. Global U.S. Intravenous Solutions Market by End Use, Revenue
                    6.4. Home
                        6.4.1. Home market estimates and forecasts 2018 to 2030 (USD Billion)
                    6.5. Hospitals
                        6.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
                    6.6. Infusion Center
                        6.6.1. Infusion center market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis, By Key Manufacturers
                    7.2. Company/Competition Categorization
                    7.3. Vendor Landscape
                        7.3.1. List of key distributors and channel partners
                        7.3.2. Key customers
                        7.3.3. Key company market share analysis, 2024
                    7.4. Company Profiles
                        7.4.1. Fresenius Kabi AG
                            7.4.1.1. Company overview
                            7.4.1.2. Financial performance
                            7.4.1.3. Product benchmarking
                            7.4.1.4. Strategic initiatives
                        7.4.2. Pfizer Inc.
                            7.4.2.1. Company overview
                            7.4.2.2. Financial performance
                            7.4.2.3. Product benchmarking
                            7.4.2.4. Strategic initiatives
                        7.4.3. Baxter
                            7.4.3.1. Company overview
                            7.4.3.2. Financial performance
                            7.4.3.3. Product benchmarking
                            7.4.3.4. Strategic initiatives
                        7.4.4. B. Braun Melsungen AG
                            7.4.4.1. Company overview
                            7.4.4.2. Financial performance
                            7.4.4.3. Product benchmarking
                            7.4.4.4. Strategic initiatives
                        7.4.5. JW Life Science
                            7.4.5.1. Company overview
                            7.4.5.2. Financial performance
                            7.4.5.3. Product benchmarking
                            7.4.5.4. Strategic initiatives
                        7.4.6. ICU Medical, Inc.
                            7.4.6.1. Company overview
                            7.4.6.2. Financial performance
                            7.4.6.3. Product benchmarking
                            7.4.6.4. Strategic initiatives
                        7.4.7. Grifols USA, LLC
                            7.4.7.1. Company overview
                            7.4.7.2. Financial performance
                            7.4.7.3. Product benchmarking
                            7.4.7.4. Strategic initiatives
                        7.4.8. Amphastar Pharmaceuticals, Inc.
                            7.4.8.1. Company overview
                            7.4.8.2. Financial performance
                            7.4.8.3. Product benchmarking
                            7.4.8.4. Strategic initiatives
                        7.4.9. Athenex, Inc.
                            7.4.9.1. Company overview
                            7.4.9.2. Financial performance
                            7.4.9.3. Product benchmarking
                            7.4.9.4. Strategic initiatives
                        7.4.10. Rockwell Medical, Inc.
                            7.4.10.1. Company overview
                            7.4.10.2. Financial performance
                            7.4.10.3. Product benchmarking
                            7.4.10.4. Strategic initiatives
                        7.4.11. Exela Pharma Sciences, LLC
                            7.4.11.1. Company overview
                            7.4.11.2. Financial performance
                            7.4.11.3. Product benchmarking
                            7.4.11.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. Intravenous solutions market, by type, 2018 - 2030 (USD Billion)
Table 3 U.S. Intravenous solutions market, by nutrients, 2018 - 2030 (USD Billion)
Table 4 U.S. Intravenous solutions market, by end use, 2018-2030 (USD Billion)
Table 5 Participant’s overview
Table 6 Financial performance
Table 7 Key companies undergoing expansions
Table 8 Key companies undergoing acquisitions
Table 9 Key companies undergoing collaborations
Table 10 Key companies launching new products
Table 11 Key companies undergoing partnerships
Table 12 Key companies undertaking other strategies

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. intravenous solutions market: market outlook
Fig. 9 U.S. intravenous solutions competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. intravenous solutions market driver impact
Fig. 14 U.S. intravenous solutions market restraint impact
Fig. 15 U.S. intravenous solutions: Product movement analysis
Fig. 16 U.S. intravenous solutions: Product outlook and key takeaways
Fig. 17 Total parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 18 Peripheral parenteral nutrition market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 19 U.S. intravenous solutions: Nutrients movement analysis
Fig. 20 U.S. intravenous solutions: Nutrients outlook and key takeaways
Fig. 21 Carbohydrates market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 22 Single dose amino acids market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 23 Vitamins and minerals market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 24 Parenteral lipid emulsion market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 26 U.S. intravenous solutions: End use movement analysis
Fig. 27 U.S. intravenous solutions: End use outlook and key takeaways
Fig. 28 Home market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 29 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 30 Infusion center market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 31 Key company categorization
Fig. 32 Strategy mapping